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Manage risk of accidental gene editing of germline 
Eric Lander and colleagues consider the ethical and safety concerns that distinguish heritable (germline) from non- 
heritable (somatic) genome editing (Nature 567, 165–168; 2019). However, unintended germline modification could 
possibly result from well-intentioned somatic genome-editing procedures. We therefore also need to consider how such 
risks can be mitigated and managed. 
For non-heritable genome editing, somatic cells from a consenting adult are edited in the laboratory and then re-
implanted. This ex vivo approach is unlikely to correct many genetic conditions. Deactivated viruses, liposomes and 
nanoparticles are therefore being tested as vehicles to convey the genome-editing machinery to faulty cells in vivo. 
Restricting delivery to specific organs — the brain, for example — might work in some cases. However, treating 
disorders such as muscular dystrophies might require large parts of the periphery, including the gonads, to be exposed 
to delivery vectors. It will therefore be crucial to establish an acceptable level of risk to the germline in such cases. 
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